Breast Cancer Canada, AstraZeneca Canada, and Illumina have announced a research grant collaboration to advance breast cancer screening and detection using precision diagnostics and AI technology.
The primary goal of this partnership is to support Canadian research teams in their efforts to develop innovative screening and analysis techniques for breast cancer detection. Ilumina will support the collaboration by providing sequencing consumables.
The collaboration aims to allocate CAD 200,000 (USD 151,381) in grants to selected projects that focus on leveraging precision or personalized technology, such as blood tests, imaging, and machine learning, to enhance accuracy and accessibility.
The projects that will be selected for funding will cover various aspects of precision oncology research and must include an AI component and participation from patient advocates. The submission period for research proposals will begin on July 3, 2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.